eFFECTOR Therapeutics, Inc., a biotechnology company, develops selective translation regulators for the treatment of cancer and other serious diseases. Description. Last Funding Type Post-IPO Equity. eFFECTOR Therapeutics (EFTR) stock price, charts, trades & the US's most popular discussion forums. The Column Group and Alexandria Venture Investments are the most recent investors. Effector Therapeutics is registered under the ticker NASDAQ:EFTR . EFTRW | eFFECTOR Therapeutics Inc. Wt Stock Overview (U.S ... SAN DIEGO, Nov. 08, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today reported financial results for the third quarter ended . Complete eFFECTOR Therapeutics Inc. stock information by Barron's. View real-time EFTR stock price and news, along with industry-best analysis. LWAC Stock: eFFECTOR Therapeutics SPAC Merger News Sends ... Historical daily price data is available for up to two years prior to today's date. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK1/2 that is in phase 2b clinical trial for the treatment of patients with . SAN DIEGO, Sept. 16, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced that company management will participate in a fireside chat at the 2021 Cantor Virtual Global Healthcare Conference at 2:40 p.m. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Complete eFFECTOR Therapeutics Inc. Wt stock information by Barron's. View real-time EFTRW stock price and news, along with industry-best analysis. Currency in USD. eFFECTOR Therapeutics Operations Inc - Company Profile and ... EFTR stock quote, chart and news. EFFECTOR Therapeutics Reports Third Quarter 2021 Financial ... eFFECTOR Therapeutics (NASDAQ: EFTR) stock price, news, charts, stock research, profile. View the latest EFTR stock quote and chart on MSN Money. eFFECTOR Therapeutics, Inc. Common Stock (EFTR) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Our data shows that SR One Capital Management, LP is the largest shareholder with 17% of shares outstanding. Description: eFFECTOR Therapeutics Inc is a clinical-stage biopharmaceutical company focused on pioneering the development of a new class of oncology drugs referred to as selective translation regulator inhibitors (STRIs).Its product candidates target the eIF4F complex and its activating kinase, mitogen-activated protein kinase 1/2 (MNK 1/2). Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Class B Common Stock: FOR AGAINST ABSTAIN NON-VOTES 4,511,250 0 0 0 3. Effector Therapeutics started at hold with $20 stock price target at Stifel Nicolaus MarketWatch. Get eFFECTOR Therapeutics Equity Warrant Exp 26th Aug 2026 (EFTRW:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. 01-21:56 GMT. EFTR | Complete eFFECTOR Therapeutics Inc. stock news by MarketWatch. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Free forex prices, toplists, indices and lots more. Free forex prices, toplists, indices and lots more. Effector Stock Statistic Functions Standard Deviation. Get a real-time eFFECTOR Therapeutics, Inc. (EFTR) stock price quote with breaking news, financials, statistics, charts and more. Published: Jan 09, 2020 By Mark Terry. 06/11/2021 02:34:58 1-888-992-3836 Free . Stock Details. eFFECTOR Therapeutics is followed by the analysts listed above. Get the latest eFFECTOR Therapeutics Inc (EFTR) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. The stock price of eFFECTOR Therapeutics (NASDAQ: EFTR) - a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, in collaboration with investigators at Baylor College of Medicine - increased by 25% during intraday . Stock quote and company snapshot for EFFECTOR THERAPEUTICS INC (EFTR), including profile, stock chart, recent news and events, analyst opinions, and research reports. Get eFFECTOR Therapeutics, Inc.'s stock price today. 5 analysts have issued twelve-month target prices for eFFECTOR Therapeutics' shares. Monday, September 20, 2021. Find real-time EFTR - eFFECTOR Therapeutics Inc stock quotes, company profile, news and forecasts from CNN Business. Enter Company or Symbol. Source: Forbes World, Symbol: EFFECTOR THERAPEUTICS INC. - COMMON STOCK. Cancer is a complex . Webull offers eFFECTOR Therapeutics Inc (EFTRW) historical stock prices, in-depth market analysis, NASDAQ: EFTRW real-time stock quote data, in-depth charts, and a fully built financial calendar to help you invest smart. LWAC Stock: eFFECTOR Therapeutics SPAC Merger News Sends Shares Skyrocketing The merger will likely close today August 25, 2021 By William White , InvestorPlace Writer Aug 25, 2021, 12:44 pm EDT . A high-level overview of eFFECTOR Therapeutics Inc (EFTR) stock. eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. eFFECTOR Therapeutics, Inc. Key Data. It focuses on small molecule drugs that act by selectively regulating translation that is known as protein synthesis. Georgian Ex-President Saakashvili Returns From Exile, Arrested On Eve Of Election. The company was founded in 2012 and is headquartered in San Diego, California. Phone Number 8589258215. eFFECTOR is a clinical stage biopharmaceutical company focused on pioneering the development of a new class of oncology drugs referred to . Overview Detailed Quote Charting Historical Prices. News. . eFFECTOR Therapeutics (EFTR) stock price, charts, trades & the US's most popular discussion forums. eFFECTOR Therapeutics, Inc. (EFTR) Add to watchlist. Market open. View a stock's price, volume, volatility and other statistics, as well as a price chart, news, performance vs. peers and a company profile. eFFECTOR Therapeutics Stock Gains On Encouraging Preclinical Zotatifin Data In . Check out our EFTR stock analysis, current EFTR quote, charts, and historical prices for Effector Therapeutics Inc stock eFFECTOR Therapeutics, Inc., a biotechnology company, develops selective translation regulators for the treatment of cancer and other serious diseases. eFFECTOR Therapeutics Stock. Dive Into Our Pipeline. eFFECTOR Therapeutics Inc NASDAQ Updated Dec 6, 2021 9:35 PM. Buy or sell eFFECTOR Therapeutics stock. 6.99 +1.28 (+22.46%) As of 12:13PM EST. Effector Therapeutics has raised a total of $220M in funding over 6 rounds. And we believe these are within reach. The stock opened with a gain of 16.38% at $6.75 and touched an intraday high of $7.04, rising 21.38% against the last close of $5.80. eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. 52wk Low 6.59. Stock analysis for eFFECTOR Therapeutics Inc (LWAC) including stock price, stock chart, company news, key statistics, fundamentals and company profile. According to present data eFFECTOR Therapeutics Inc - Warrants (26/08/2026)'s EFTRW shares and potentially its market environment have been in bearish . eFFECTOR Therapeutics, Inc. (EFTR) stock plummeted over -2.81% intraday to trade at $-0.09 a share on NASDAQ. eFFECTOR's STRI product candidates target the eIF4F complex and its activating kinase, mitogen-activated protein kinase 1/2 (MNK). Their latest funding was raised on Aug 26, 2021 from a Post-IPO Equity round. CSVI Crosses Above Key Moving Average Level. Josh Enomoto on InvestorPlace | September 28, 2021. eFFECTOR Therapeutics Stock Might Be Worth the Risk in Small Quantities. eFFECTOR Therapeutics stock quote and EFTR charts. Company profile page for eFFECTOR Therapeutics Operations Inc including stock price, company news, press releases, executives, board members, and contact information Gross . It focuses on small molecule drugs that act by selectively regulating translation that is known as protein synthesis. Company Type For Profit. More. eFFECTOR Therapeutics Inc Change company Symbol lookup Short Term. Pfizer and eFFECTOR Therapeutics inked a global license and collaboration deal to develop small-molecule inhibitors of eukaryotic initiation factor 4E, also known as eIF4E. Proposal 3 - The "Incentive Plan Proposal" - to approve the eFFECTOR Therapeutics, Inc. 2021 Incentive Award Plan, including the initial share reserve under the plan. 06:49 AM ET. Pfizer and eFFECTOR Ink $507 Million Cancer Deal. According to present data eFFECTOR Therapeutics's EFTR shares and potentially its market environment have been in bearish cycle last 12 months (if exists). We note that hedge funds don't have a meaningful investment in eFFECTOR Therapeutics. Quote. View the latest EFTR stock quote and chart on MSN Money. View real-time stock prices and stock quotes for a full financial overview.
Women's Handball Ball Size, Hong Kong, China Border Opening, Dmca Takedown Notice Sample, Fgm-148 Javelin Manual, Problems With New Chevy Trucks,